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Running title: MAIT cell development.  45 
 3 
Mucosal-associated invariant T (MAIT) cells detect microbial vitamin B2 derivatives presented 46 
by the antigen-presenting molecule, MR1. Here, we define three developmental stages and 47 
checkpoints for the MAIT cell lineage in humans and mice. Stage 1 and 2 MAIT cells predominate 48 
in thymus, while stage 3 cells progressively increase extrathymically. Transition through each 49 
checkpoint is regulated by MR1, whereas the final checkpoint that generates mature functional 50 
MAIT cells is controlled by multiple factors, including the transcription factor PLZF and 51 
microbial colonisation. Furthermore, stage 3 MAIT cells are expanded in CD1d-deficient mice, 52 
suggesting a niche shared between MAIT cells and NKT cells. Accordingly, this study maps the 53 
developmental pathway and checkpoints that control the generation of functional MAIT cells.  54 
 55 
MAIT cells are a specialized T cell lineage that detects vitamin-B derivatives such as 5-(2-56 
oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU), presented by the major histocompatibility 57 
complex (MHC) class-I-related protein, MR11,2,3,4,5. Both the MAIT T cell receptor (TCR) and MR1 are 58 
evolutionarily conserved suggesting strong selective pressure to maintain MAIT cell-mediated 59 
immunity6,7. These cells express a semi-invariant TCR comprising an invariant TRAV1-2 TRAJ33 60 
(TCR alpha variable 1-2+  TCR alpha joining 33) chain in humans (TRAV1+TRAJ33+ in mice) and a 61 
constrained range of TCR chains, with a bias toward TCR beta variable (TRBV)6 and TRBV20 in 62 
humans and TRBV19 and TRBV13 in mice. MAIT cells are abundant, representing ~5-50% of T cells 63 
in different human tissues, although their numbers vary widely between individuals8,9,10,11.  Moreover, 64 
they play important roles in the immunity to infection with a broad range of pathogens9,12,13, and are also 65 
involved in autoimmunity and other inflammatory responses24.  Given the functional significance of 66 
MAIT cells, and their wide variability, it is important to understand the factors that control their 67 
development and maturation. 68 
 69 
MAIT cells develop in the thymus, where they undergo positive selection and lineage commitment upon 70 
interaction with MR1-expressing CD4+CD8+ double positive (DP) thymocytes1,4,14. While 71 
phenotypically distinct subsets of MAIT cells have been defined, including CD4+, CD4-CD8- and CD4-72 
CD8+ populations11,15, the developmental pathway that underpins the production and maturation of 73 
MAIT cell remains unclear. In humans, blood MAIT cells are often defined by expression of TRAV1-2 74 
in conjunction with CD161 and CD218 (IL-18Rα)8,16,17,18. However, when these markers are acquired 75 
during the development of MAIT cells is unknown, so it is unclear if these can be used to study MAIT 76 
cell development in the thymus. With the recent development of MR1 tetramers it is now possible to 77 
specifically detect and isolate MAIT cells in mice and humans2,15,19,20. Here, we identify previously 78 
unknown populations of MAIT cells in mouse and human thymus and delineate a three-stage 79 
developmental pathway in both species, defining key control points and factors that regulate the 80 
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generation of these cells. Thus, we have mapped the development of MAIT cells in mice and humans 81 
and demonstrated the potential for this model to understand how this process is regulated. 82 
 83 
RESULTS 84 
Identification of mouse thymic MAIT cell progenitors 85 
To understand MAIT cell development, MR1-5-OP-RU tetramers were used to characterize MAIT cells 86 
in the thymus and peripheral lymphoid tissues of mice. This identified a novel population of 87 
CD24+CD44- MAIT cells that were exclusively present in thymus, whereas in peripheral organs 88 
essentially all MAIT cells were CD24-CD44+ (Fig. 1a). Control MR1 tetramers loaded with the non-89 
agonist folate-derivative acetyl-6-formylpterin Ac-6-FP21 failed to stain MAIT cells from these organs 90 
(Fig. 1a), confirming specific staining. Single cell TCR sequence analysis of both CD24+CD44- and 91 
CD24-CD44+ populations indicated that both populations utilized an invariant TRAV1-TRAJ33 TCR 92 -chain, paired with a limited range of TCR -chains (TRBV13 and TRBV19), characteristic of the 93 
MAIT cell lineage (Supplementary Table 1)4. Comparison of CD24+CD44- and CD24-CD44+ MAIT 94 
cells within the thymus indicated that CD24+CD44- MAIT cells had low expression of CD103, CD122 95 
(IL-βRȕ), CD1β7 (IL-7Rα), CDβ18 (IL-18R), CD278 (ICOS) and NK1.1 (CD161), but higher 96 
expression of CD62L and CD69 compared to CD24-CD44+ MAIT cells (Fig. 1b). Staining of thymus 97 
MAIT cells enriched by MR1-5-OP-RU tetramer and magnetic beads indicated an additional 98 
subpopulation of CD24-CD44- MAIT cells (Fig. 1c). Thus, based on their cell-surface phenotype, we 99 
tentatively defined these populations as stage 1 (CD24+CD44-), stage 2 (CD24-CD44-) and stage 3 100 
(CD24-CD44+) MAIT cells (Fig. 1c). The vast majority of stage 1 thymic MAIT cells were small (FSC 101 
(forward scatter)lo) CD4+ or CD4+CD8+ DPs, a phenotype that is typically associated with immature T 102 
cells in the thymus, and which also defines the earliest stage in the development of CD1d-restricted 103 
natural killer T (NKT) cells22. Stage 2 cells were larger, mostly CD4+CD8-, whereas stage 3 MAIT cells 104 
were the largest and resembled mature MAIT cells in peripheral organs, being mostly CD4-CD8- or 105 
CD8+ (Fig. 1a,c). Most CD8+ MAIT cells in thymus expressed CD8αȕ heterodimers, while those in the 106 
periphery express CD8αα homodimers or CD8αȕ heterodimers (Fig. 1a), suggesting further extrathymic 107 
maturation of MAIT cells. Collectively, these data support the presence of three distinct stages of MAIT 108 
cell development within mouse thymus.  109 
 110 
Functionally mature stage 3 MAIT cells arise through ontogeny  111 
To investigate the developmental progression of the three stages of thymic MAIT cells, we performed 112 
an ontogeny study for mouse thymic MAIT cell subsets at 2, 4 and 8 weeks of age. Stage 1 CD24+CD44- 113 
MAIT cells were the major subset (>50%) at 2 weeks, declining to ~30% at 4 weeks and ~10% of thymic 114 
MAIT cells in the adult 8-week-old mouse thymus (Fig. 2a,b). Conversely, the proportion of stage 3 115 
CD24-CD44+ MAIT cells was low (~20%) at 2 weeks and gradually increased with age (~60% at 4 116 
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weeks and ~80% at 8 weeks) (Fig 2a,b), supporting the concept of developmental progression of MAIT 117 
cells from stage 1 to stage 3.  118 
 119 
To determine the stage where MAIT cells gained functional maturity, we examined the expression of 120 
transcription factors known to regulate their cytokine production. Stage 1 and 2 cells had low expression 121 
of RORȖt and T-bet (Fig. 2c), suggesting little capacity to secrete IL-17 and IFN-15, while stage 3 MAIT 122 
cells expressed either RORȖt or T-bet (Fig. 2c), suggesting functional competence. Analysis of RORȖt-123 
GFP reporter mice confirmed that only stage 3 MAIT cells expressed GFP (Supplementary Fig. 1). 124 
The proportion of stage 3 MAIT cells that expressed RORt or T-bet did not significantly change 125 
throughout ontogeny (data not shown). Stimulation of MAIT cells with PMA and ionomycin revealed 126 
that stage 3 MAIT cells, but not stage 1 and 2 MAIT cells, were capable of IL-17 and IFN- production 127 
(Fig. 2d). Accordingly, the transition to stage 3 correlated with the acquisition of functional potential of 128 
mouse MAIT cells (Fig. 2d), supporting the concept that stage 1 and 2 MAIT cells are immature MAIT 129 
cell precursors. 130 
 131 
Stage 1 and stage 2 MAIT cells develop into stage 3 MAIT cells 132 
To directly investigate the precursor-progeny relationship of the three stages of thymic MAIT cells we 133 
established an in vitro MAIT cell development system using an adaptation of the OP9 cell-thymocyte 134 
co-culture system23. Because the numbers of thymus MAIT cell subsets in wild-type mice were very 135 
low, we used transgenic mice that express the TRAV1-TRAJ33 TCR chain on a TCR-constant region-136 
null background (C-/-), in which thymic MAIT cells are far more abundant (Supplementary Figure 2). 137 
After 5 days of co-culture with OP9 cells, FACS-sorted stage 1 MAIT cells had started to differentiate 138 
into stage 2 and stage 3 cells (Fig. 3a,b). Similarly, many stage 2 MAIT cells had progressed to stage 3, 139 
whereas stage 3 cells maintained their mature CD24-CD44+ phenotype (Fig. 3a,b). Optimal 140 
differentiation from stage 1 and stage 2 MAIT cells into stage 3 MAIT cells required the presence OP9 141 
cells (Fig. 3a,b), indicating a key role for stromal cell-derived factors in this process. We also cultured 142 
stage 1, 2 and 3 MAIT cells with OP9 cells engineered to express Notch ligand, Delta-like 1, (OP9-DL1) 143 
and found that signalling via DL1 was not required for maturation of TCR+ MAIT cell precursors (data 144 
not shown). Addition of an MR1-blocking antibody completely abrogated the progression of stage 1 to 145 
stage 3 MAIT cells, and partially inhibited the differentiation or survival of stage 2 and stage 3 cells, as 146 
reflected by a sharp reduction in cell numbers by day 5 (Fig.3a,b). These data are consistent with the 147 
lack of MAIT cells in MR1-deficient mice1,11,15, and indicate that the expression of MR1 is critical for 148 
both the initial development and further differentiation and/or survival of MAIT cells. 149 
 150 
We also isolated MAIT cell subsets from wild-type mice and cultured them with OP9 cells. Because 151 
these cells were less frequent, we were unable to isolate sufficient numbers of the intermediate stage 2 152 
 6 
cells. Nonetheless, stage 1 cells progressed to stages 2 and 3 after 5 days of co-culture with OP9 cells, 153 
whereas stage 3 cells maintained their mature phenotype (Fig.3a,b), indicating a similar developmental 154 
profile and kinetics as the TRAV1-TRAJ33 TCR-transgenic cells. These data indicate that 155 
differentiation of mouse MAIT cells can be defined by a three-stage sequential pathway from 156 
CD24+CD44- (stage 1), via CD24-CD44- (stage 2), to CD24-CD44+ (stage 3).  157 
 158 
PLZF controls the maturation and function of MAIT cells 159 
The transcription factor PLZF, known to be important for the development of NKT cells, innate 160 
lymphoid cells (ILC) and some  T cells24,25,26,27 is expressed by MAIT cells in humans and mice11,15. 161 
The production of normal numbers of MAIT cells depends upon this factor, although notably, a residual 162 
population of MAIT cells remained in mice that were deficient for PLZF (PLZF-null mice)15. In wild-163 
type mice, PLZF was not detected in stage 1, showed heterogeneous expression in stage 2, and was fully 164 
expressed in stage 3 MAIT cells (Fig. 4a). In PLZF-null mice stage 1 and stage 2 MAIT thymic cells 165 
were intact, whereas stage 3 MAIT cells were completely absent, in contrast to wild-type mice where 166 
stage 3 MAIT cells were the major population (Fig. 4b,c). Residual MAIT cells in the periphery of 167 
PLZF-null mice were predominantly CD24-CD44- and CD4+CD8- (Fig. 4b), and lacked CD218, CD127 168 
and CD103 expression (data not shown), indicating they were blocked at stage 2. Stimulation (PMA 169 
and ionomycin) of the residual MAIT cells isolated from thymus, spleen and lymph nodes of PLZF-null 170 
mice did not induce cytokine secretion, compared to wild-type MAIT cells, which expressed either IL-171 
17A or IFN- (Fig. 4d). This suggests that progression to stage 2 is PLZF-independent, but maturation 172 
to stage 3 and acquisition of effector function is PLZF-dependent, and can occur after stage 2 cells leave 173 
the thymus, because in the absence of the PLZF-driven maturation, MAIT cells remain immature in the 174 
thymus and peripheral tissues. 175 
 176 
miRNA controls the development of MAIT cells 177 
Because microRNAs (miRNAs) play important roles in regulating gene expression and profoundly 178 
influence development and function of NKT cells28, we next examined the role of Drosha, a member of 179 
the ribonuclease-III superfamily that initiates miRNA processing in the nucleus28,29 in MAIT cell 180 
maturation. We used Drosha-floxed mice crossed with transgenic mice expressing Cre under the control 181 
of the CD4 promoter (Droshafl/flCD4-Cre) mice, which have a marked Drosha deficiency from the 182 
CD4+CD8+ DP thymocyte stage30. The vast majority of MAIT cells in the thymus of Droshafl/fl CD4-183 
Cre mice were stage 1 cells, whereas stage 2 and stage 3 MAIT cells were both significantly reduced 184 
compared to Droshafl/+ CD4-Cre heterozygous control mice (Fig. 5a,b), suggesting that development 185 
beyond stage 1 is dependent on miRNAs. Despite the developmental impairment in the Droshafl/fl CD4-186 
Cre thymus, stage 3 CD44+ MAIT cells were still detected in spleen and lymph nodes of these mice, 187 
albeit at diminished numbers compared to heterozygous controls (Fig. 5a,b). We also observed a 188 
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significant reduction in NKT cells within thymus, spleen and lymph nodes of Droshafl/fl CD4-Cre mice 189 
compared to control mice (Supplementary Fig. 3a), which is consistent with observations in Dicer-190 
deficient mice (another member of the ribonuclease-III superfamily31). Accordingly, miRNAs control 191 
MAIT cell development beyond stage 1. 192 
 193 
MAIT cell development is impaired in germ-free mice 194 
MAIT cells were previously reported to be absent in germ-free mice1, thus we examined whether a 195 
developmental block occurred at a specific stage, comparing germ-free mice to specific-pathogen-free 196 
(SPF) control mice. The numbers of MAIT cells in the thymus and spleen of germ-free mice were 197 
significantly reduced (Fig. 5a,b). Moreover, thymic stage 3 CD44+ MAIT cells were diminished (Fig. 198 
5a,b), while stage 1 CD24+CD44- MAIT cells were increased in frequency, but not number, in germ-199 
free mice (Fig.5a and data not shown). In contrast, there was no difference in the number of NKT cells 200 
in germ-free mice compared to SPF controls (Supplementary Fig. 3b). 201 
  202 
Since IL-18 expression is diminished in germ-free mice32 and because MAIT cells expressed IL-18R 203 
during their intrathymic maturation (Fig. 1), we examined whether the loss of IL-18 would impact on 204 
MAIT cell development. Similar to germ-free mice, IL-18-deficient mice displayed reduced thymic 205 
MAIT cell numbers and a decrease in the frequency of thymic stage 3 CD24-CD44+ MAIT cells, with 206 
an increase in the frequency, but not number, of stage 1 CD24+CD44- MAIT cells compared to wild-207 
type mice (Supplementary Fig. 4a,b). Furthermore, MAIT cells were significantly reduced in the spleen 208 
and lymph nodes of IL-18-deficient mice compared to wild-type mice (Supplementary Fig. 4a). 209 
Paradoxically, IL-18Rαdeficient mice showed normal MAIT cell development and maturation within 210 
the thymus, spleen and lymph nodes (Supplementary Fig. 4c,d). Comparison of IL-18-deficient and 211 
IL-18Rα-deficient mice may be complicated because IL-18 can signal through another receptor, the Na-212 
Cl co-transporter33 whereas another cytokine, IL-37, can signal through IL-18R34. Thus, MAIT cell 213 
development and maturation is impaired in germ-free mice, suggesting an important role for commensal 214 
bacteria and IL-18 in this process.  215 
 216 
MAIT cells are over-represented in CD1d-deficient mice 217 
Because MAIT cells and NKT cells have some similarities, such as a dependence on PLZF and selection 218 
by DP thymocytes, we examined MAIT cell development in CD1d-deficient mice that lack both CD1d 219 
and CD1d-restricted NKT cells. CD1d-deficient mice showed increased numbers of MAIT cells in 220 
thymus, spleen (Figure 6a,b and Supplementary Fig. 5) and liver (data not shown) compared to wild-221 
type controls on both BALB/c and C57BL/6 backgrounds, and this was particularly apparent on the 222 
BALB/c background (Fig. 6a,b). As previously reported15, a higher percentage of MAIT cells expressed 223 
the co-receptor CD8 in BALB/c compared to C57BL/6 mice, and this was seen in both wild-type and 224 
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CD1d-deficient mice (Fig. 6a and Supplementary Fig. 5). In terms of MAIT cell development, while 225 
numbers of stage 1 and 2 MAIT cells were not altered in CD1d-deficient mice, stage 3 CD24-CD44+ 226 
MAIT cells were far more numerous in thymus and spleen of CD1d-deficient mice compared to wild-227 
type controls (Figure 6a,b and Supplementary Fig. 5). Conversely, NKT cell numbers were similar in 228 
thymus and spleen of MR1-deficient and wild-type mice (data not shown). Taken together, these data 229 
suggest that MAIT cells might compete with NKT cells for factors or a shared niche during their 230 
maturation in the thymus.  231 
 232 
Identification of MAIT cell precursors in the human thymus 233 
We next determined whether MAIT cell development in humans follows a similar developmental 234 
pathway as in mice. We analysed MAIT cells in human thymus, umbilical cord blood, young peripheral 235 
blood (matched from thymus donors) and adult peripheral blood, using human MR1-5-OP-RU tetramers 236 
in combination with other markers commonly used to identify MAIT cells, including TRAV1-2, CD161 237 
and CD2188,16,17. MAIT cells (defined as TRAV1-2+ MR1-5-OP-RU tetramer+) were detected in all 238 
human thymus samples, although they were much less frequent (<0.05%) than in adult human blood, 239 
where they typically represent 2-5% of CD3+ T cells15. Because they were so infrequent in human 240 
thymus, TRAV1-2+ cells were first enriched using magnetic beads, which yielded a clear population of 241 
MAIT cells, ranging from 0.08-0.45% of TRAV1-2+ thymocytes (Fig. 7a,b). The frequency of MAIT 242 
cells as a percentage of TRAV1-2+ cells increased in cord blood, young blood and adult blood (Fig. 243 
7a,b), respectively, suggesting that peripheral expansion is responsible for the abundance of MAIT cells 244 
in adult humans.  245 
 246 
The vast majority of MAIT cells from adult blood co-expressed CD218 and CD161 while most (up to 247 
97%) thymic MAIT cells were CD218-CD161- (Fig. 7a,b).  The majority of MAIT cells in young blood 248 
and cord blood were CD218+CD161+ (Fig. 7a). Thus, CD218-CD161- MAIT cells were predominant in 249 
human thymus and they gradually diminished in increasingly mature blood samples, suggesting that they 250 
were immature precursors (Fig. 7a,c). Furthermore, whereas blood MAIT cells were predominantly 251 
CD4-CD8- or CD4-CD8+ (Fig. 7a), roughly half of thymus MAIT cells were either CD4+CD8+ or 252 
CD4+CD8- (Fig. 7a). Moreover, analysis of paired thymus and blood samples showed that CD4+ MAIT 253 
cell populations declined sharply between thymus and matched blood (Fig. 7d). Accordingly, most 254 
human thymic MAIT cells were markedly distinct from MAIT cells in blood.  255 
 256 
We also performed an ontogeny study of thymus and blood MAIT cells in matched thymus and blood 257 
samples from 18 different donors ranging from 5 days to 14 years of age. The analysis indicated that 258 
MAIT cell frequencies (as a percentage of TRAV1-2+ cells) remain relatively low and stable in the 259 
thymus (0.1-0.3% of TRAV1-2+ cells) regardless of age (Fig. 7e), while in contrast, MAIT cell 260 
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frequency gradually increased in peripheral blood with age (5 days to 14 years), from less than 1% to up 261 
to 60% of TRAV1-2+ cells and from less than 0.02% to up to 3.5% of CD3+ T cells  (Fig. 7e,f). Thus, 262 
the characteristically high numbers of MAIT cells in human blood is a result of gradual peripheral 263 
expansion with age. 264 
 265 
Further analysis of human CD161- MAIT cells based on CD27 expression, indicated that CD161-CD27- 266 
subset was exclusively found in thymus, whereas CD161-CD27+ MAIT cells were detected at low 267 
frequency in cord blood (~22%) and young blood (~13%) and were essentially absent from adult blood 268 
(~1%). Conversely, CD161+CD27+/lo MAIT cells were rare in thymus (~10%) and abundant in blood 269 
(Fig. 7a,g). Thus, we tentatively defined three distinct stages of MAIT cell development in human 270 
thymus: stage 1 (CD161-CD27-); stage 2 (CD161-CD27+) and stage 3 (CD161+CD27+/lo). Further 271 
analysis of these stages demonstrated the decline in stage 1 and 2 and the rise in stage 3 with increasingly 272 
mature human tissues (Fig. 7a,g). In line with this maturation pathway, and similar to that in mice, 273 
human stage 1 MAIT cells were predominantly CD4+CD8+, stage 2 MAIT cells were CD4+, CD4+CD8+ 274 
cells, and CD4-CD8+ cells whereas stage 3 MAIT cells were mostly CD4-CD8- or CD8+ (Fig. 8a), the 275 
latter more closely resembling MAIT cells found in human blood (Fig. 8a). Taken together, the 3-stage 276 
MAIT cell development pathway we have identified in human thymus roughly parallels the pathway we 277 
have mapped for mouse thymus (Supplementary Fig. 6). 278 
 279 
Many peripheral CD8+ MAIT cells express CD8αα homodimers rather than CD8αȕ heterodimers (Fig. 280 
8a)17. Given that most human thymocytes express CD8 heterodimers, we determined where in the 281 
three-stage development pathway human MAIT cells began to express CD8 homodimers. Similar to 282 
MAIT cells in mouse thymus, essentially all CD8+ MAIT cells in the human thymus expressed the 283 
CD8αȕ heterodimer, regardless of whether they were at stage 1, β or γ of development (Fig. 8a). 284 
However in thymus-matched blood samples, a high proportion of blood MAIT cells were CD8αα+ (Fig. 285 
8a). This distinct CD8 profile of thymic MAIT cells is consistent with earlier reports suggesting that 286 
CD8αα MAIT cells develop from a pool of CD161+CD8αȕ T cells17,18. Furthermore, this also suggests 287 
that stage 3 MAIT cells in human thymus were not recirculating cells from the periphery, but rather a 288 
recently developed population arising from stage 2 CD161-CD27+ MAIT cells.  289 
 290 
Functional maturation begins at stage 3 in MAIT cell development 291 
We next examined if the 3 stages of human thymic MAIT cells displayed a similar pattern of 292 
transcription factors compared to the same stages in mice. Akin to mouse thymic MAIT cells, the 293 
expression of PLZF, T-bet and RORt increased between stage 2 and 3 (Fig. 8b) although RORt was 294 
not highly expressed in mature MAIT cells (Fig. 8b). In contrast to mouse stage 3 MAIT cells where T-295 
bet and RORt were mutually exclusive, these factors were co-expressed in human stage 3 MAIT cells 296 
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(Fig. 8b). A small subset of stage 1 MAIT cells expressed RORt, which likely reflected their recent 297 
transition from CD4+CD8+ DP thymic precursors that are RORt+ (Fig. 8b). 298 
 299 
To examine their functional competence, human thymic and matched blood MAIT cells were tested for 300 
IFN-, TNF and IL-17A following PMA and ionomycin stimulation (Fig. 8c and data not shown). 301 
While a subset (<25%) of stage 3 thymic MAIT cells produced IFN- and TNF, the matched blood stage 302 
3 cells were far superior in their cytokine producing potential, with the majority (>80%) producing both 303 
IFN- and TNF (Fig. 8c,d). We were unable to detect IL-17A production by any of these MAIT cell 304 
subsets (data not shown), which probably reflects the relatively low expression of RORt by these cells. 305 
Thus, human MAIT cells are functionally competent at stage 3, but continue their functional maturation 306 
extrathymically. 307 
 308 
DISCUSSION 309 
Here we have identified precursor populations for the MAIT cell lineage in the thymus and mapped a 310 
three-stage pathway in both mice and humans. In both species, only stage 3 cells produced cytokines 311 
and these resembled MAIT cells in peripheral organs, although further extrathymic maturation occurred 312 
for human stage 3 cells. Based on the presence of some stage 2 cells in human blood, especially in cord 313 
blood, and in PLZF-null mice, we suggest that MAIT cells can first emigrate from the thymus at stage 314 
2 and continue their maturation and expansion extrathymically. 315 
 316 
Our data provide a more complete view of MAIT cell development compared to previous studies that 317 
relied on surrogate phenotypic markers such as TRAV1-2+CD161+ and to identify MAIT cells in 318 
humans18 or the use of transgenic TCR systems or RORγt to detect MAIT cells in mice11,35,36. The 319 
surrogate markers for human MAIT cells exclude CD161- stage 1 and stage 2 MAIT cells, limiting 320 
earlier studies to the minor subset of mature stage 3 cells in human thymus18. Furthermore, we found 321 
that ~50% of TRAV1-2+CD161+ cells from human thymus failed to bind MR1-5-OP-RU tetramer (data 322 
not shown) suggesting many of these are not MAIT cells. Similarly, while the use of RORγt-GFP 323 
combined with CD44 should identify many of the mature stage 3 MAIT cells in mice36, this strategy will 324 
miss immature stage 1 and stage 2 CD44- MAIT cells and mature stage 3 MAIT cells that lack RORγt.  325 
 326 
There are some similarities between the development of MAIT cells and CD1d-restricted NKT cells. 327 
Both lineages depend on PLZF expression for normal maturation, and both are dependent on miRNAs 328 
regulated by Drosha. However, there are some important differences in the development of these 329 
lineages. Firstly, PLZF is highly expressed very early in NKT cell development and is downregulated 330 
in most mature NKT cells25,27, with the exception of IL-4-producing NKT2 cells37,38. In contrast, PLZF 331 
is expressed late in MAIT cell development, governing their final maturation step to generate functional 332 
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stage 3 MAIT cells, and is maintained at high levels by these cells. Upon maturation, most NKT cells 333 
upregulate NK1.1 and CD69 in mice and they are either CD4+ or CD4-CD8-. Conversely, most mature 334 
mouse MAIT cells lacked NK1.1 and downregulated CD69 upon maturation, and many expressed CD8. 335 
MAIT cell maturation was impaired in germ-free mice, whereas NKT cell maturation was intact, and, 336 
as previously shown, the SLAM adaptor protein (SAP) is critical for NKT cell development39, whereas 337 
MAIT cells appear to be SAP-independent11. Furthermore, our observation that MAIT cells are over-338 
represented in CD1d (NKT cell)-deficient mice suggests that these cells may compete for an 339 
environmental niche. This may partly explain why CAST/EiJ mice, which have less NKT cells40, have 340 
higher numbers of MAIT cells compared to C57BL/6 controls36. It follows that careful consideration is 341 
required when studying NKT cell deficient mice as these will differ from wild-type control mice not 342 
only because they lack NKT cells, but also because they have increased MAIT cells. 343 
 344 
While the developmental sequence for MAIT cells in mice and humans has many parallels, there were 345 
also some distinctions. Although we detected stage 3 MAIT cells in human thymus, these were in the 346 
minority and were only partially functional compared to stage 3 MAIT cells in mouse thymus. Human 347 
peripheral blood MAIT cells accumulate with age, and also acquire greater cytokine producing capacity 348 
and many switch from CD8 to CD8 expressing cells. In further contrast to mouse MAIT cells, 349 
neither thymus nor blood MAIT cells from humans produced IL-17. Given that human MAIT cells 350 
isolated from liver and female genital tract can produce IL-1710,41, this suggests that further environment-351 
dependent extrathymic maturation influences human MAIT cell function. We hypothesize that this 352 
peripheral expansion and maturation is shaped by exposure to microbial antigens over time, which is 353 
also supported by our studies with germ-free mice where stage 3 MAIT cells were significantly reduced 354 
in thymus and periphery and also by a recent paper that demonstrated microbial mediated expansion of 355 
peripheral MAIT cells in a mouse model of Salmonella infection42.  356 
 357 
In summary, we have defined thymic precursors for the MAIT cell lineage and mapped a three-stage 358 
pathway for MAIT cell maturation in mice and humans that is controlled by developmental checkpoints. 359 
We have identified key factors that control this process and most importantly, this study provides a 360 
foundation for future studies to better understand the factors that regulate the highly abundant, yet highly 361 
variable, MAIT cell lineage.   362 
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Figure Legends 363 
 364 
Figure 1. Identification of distinct MAIT cell subsets in mouse thymus  365 
(a) Flow cytometric analysis of TCRȕ+MR1-5-OP-RU+ MAIT cells in mouse thymus, spleen, lung and 366 
lymph nodes for expression of CD24, CD44, CD4, CD8 and CD8ȕ.  MR1-Ac-6-FP tetramer was used 367 
as a negative control. (b) Phenotypic analysis of CD24+CD44- and CD24-CD44+ thymic MAIT cells for 368 
ICOS, NK1.1 (CD161), CD62L, CD69, CD103, CD122 (IL-2R), CD127 (IL-7R) and CD218 (IL-18R), 369 
CD24+CD44- MAIT cells in blue, CD24-CD44+ MAIT cells in red, CD4+CD8+ double positive (DP) 370 
thymocytes in black. (c) Identification of three populations of thymic MAIT cells following magnetic 371 
bead enrichment. Flow cytometric analysis of 3 stages of MAIT cells defined using CD24 and CD44. 372 
Stage 1 (S1, CD24+CD44-) in blue, stage 2 (S2, CD24-CD44-) in green and stage 3 (S3, CD24-CD44+) 373 
in red. Flow cytometric analysis of stage 1, stage 2 and stage 3 MAIT cells for forward scatter (FSC) 374 
and CD4/CD8 co-receptor expression. Data are representative from a total of 6 mice from 3 independent 375 
experiments (a), or from 2 independent experiments from 5-pooled thymi (b) or from at least 10 376 
independent experiments (c). 377 
 378 
Figure 2. Ontogeny, transcriptional and functional potential of mouse MAIT cells 379 
(a) Flow cytometric analysis of MR1-5-OP-RU tetramer enriched pooled thymi from 2, 4 or 8-week-old 380 
C57BL/6 mice for CD24 and CD44 expression. (b) Percentages of stage 1, stage 2 and stage 3 MAIT 381 
cells in 2, 4 and 8-week-old mice thymi. (c) RORȖt and T-bet expression on stage 1, stage 2 and stage 3 382 
MAIT cells from enriched C57BL/6 wild-type (WT) mouse thymi. (d) Flow cytometric analysis of stage 383 
1, stage 2, and stage 3 thymic MAIT cells stimulated with PMA/ionomycin, and examined for IFN-Ȗ 384 
and IL-17A expression. Data are representative of 2 independent experiments with a total of 4 separate 385 
samples (pools of 5 thymi) per age group (a, b; mean ± SEM), or of 3 independent experiments from 4-386 
5 week old mice (c , d).  387 
 388 
Figure 3. Precursor product relationship of mouse MAIT cells 389 
(a) Flow cytometric analysis of stage 1, stage 2, and stage 3 TRAV1-TRAJ33 TCR transgenic C-/- 390 
thymic MAIT cells; and stage 1 and stage 3 WT thymic MAIT cells purified by flow cytometric sorting 391 
(day 0) and at the end of culture (day 5) in the presence or absence of OP9 cells, with or without anti-392 
MR1 antibody (α-MR1), and analyzed for the expression of CD24 and CD44. (b) Percentages and 393 
numbers of stage 3 MAIT cells at the end of culture.  Data are representative of 3 independent 394 
experiments (a, b; mean ± SEM).    395 
 396 
Figure 4. PLZF controls development of MAIT cells 397 
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(a) Flow cytometric analysis of stage 1, stage 2 and stage 3 cells thymic MAIT cells from WT mice for 398 
PLZF expression. (b) Flow cytometric analysis of MAIT cells from MR1-5-OP-RU enriched thymus, 399 
spleen, and lymph nodes from WT and PLZF-null mice for CD24, CD44, and CD4/CD8 co-receptor 400 
expression. (c) Numbers of MAIT cells in thymus, spleen and lymph nodes of WT and PLZF-null mice, 401 
and percentages of stage 1, stage 2 and stage 3 MAIT cells in enriched thymus, spleen and lymph nodes 402 
of WT and PLZF-null mice. (d) Flow cytometric analysis of MAIT cells in unstimulated (Unstim) and 403 
PMA/ionomycin stimulated (Stim) enriched thymus, spleen and lymph nodes from WT and PLZF-null 404 
mice, examined for IFN-Ȗ and IL-17A expression. *P<0.1 **P<0.01 ***P<0.001 (Mann-Whitney rank 405 
sum U test (c)). ND = not detectable. Data are representative of 3 independent experiments with a total 406 
of 9 mice per group (b, c; mean ± SEM) or of 2 independent experiments with a total of 6 mice per group 407 
(d).  408 
 409 
Figure 5. MAIT cell development is impaired in Drosha KO mice and germ-free mice. 410 
(a) Flow cytometric analysis of MAIT cells from MR1-5-OP-RU tetramer enriched thymus, spleen, 411 
lymph nodes from Droshafl/+ CD4-Cre heterozygous control mice and Droshafl/flCD4-Cre mice for 412 
CD24, CD44 and CD4/CD8 co-receptor expression. (b) Percentages of stage 1, stage 2 and stage 3 413 
MAIT cells in enriched thymus of Droshafl/+ CD4-Cre and Droshafl/flCD4-Cre mice. Absolute numbers 414 
and percentage of stage 3 MAIT cells from thymus of Droshafl/+ CD4-Cre and Droshafl/flCD4-Cre mice. 415 
Absolute numbers and percentage of MAIT cells of TCRȕ+ cells in spleen and lymph nodes of Droshafl/+ 416 
CD4-Cre and Droshafl/flCD4-Cre mice. (c) Flow cytometric analysis of MAIT cells from MR1-5-OP-417 
RU tetramer enriched thymus and spleen from control specific-pathogen-free (SPF) and germ-free (GF) 418 
mice for CD24, CD44, and CD4/CD8 co-receptor expression. (d) Absolute numbers and percentage of 419 
stage 3 MAIT cells of TCRȕ+ in thymus of SPF and GF mice. Absolute numbers and percentage of 420 
MAIT cells of TCRȕ+ cells in spleens of SPF and GF mice. *P<0.1 **P<0.01 ***P<0.001 (Mann-421 
Whitney rank sum U test (b, d)). Data are representative of 3 independent experiments with a total of 8 422 
mice per group (a, b; mean ± SEM) or of 2 independent experiments with a combined total of 11-15 423 
mice per group (c, d; mean ± SEM).  424 
 425 
Figure 6. MAIT cell numbers are increased in CD1d-deficient mice. 426 
(a) Flow cytometric analysis of MAIT cells from thymus and spleen from BALB/c WT and BALB/c 427 
CD1d-deficient mice for CD24, CD44 and CD4/CD8 co-receptor expression. (b) Percentages of CD44+ 428 
MAIT cells in the thymus of BALB/c WT, BALB/c CD1d-deficient, C57BL/6 WT and C57BL/6 CD1d-429 
deficient mice. Absolute numbers and percentages of MAIT cells of TCRȕ+ cells in thymus and spleen 430 
from BALB/c WT, BALB/c CD1d-deficient, C57BL/6 WT and C57BL/6 CD1d-deficient mice. *P<0.1 431 
**P<0.01 ***P<0.001 (Mann-Whitney rank sum U test (b)). Data are representative of 3 independent 432 
experiments with a total of 6 mice per group (a, b; mean ± SEM). 433 
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 434 
Figure 7. Identification of distinct MAIT cell subsets in humans 435 
(a) First two panels: Flow cytometric analysis of CD3+ cells from adult blood, young blood from thymus 436 
donors, cord blood and human thymus samples enriched for TRAV1-2+ cells for MR1-Ac-6FP+ or MR1-437 
5-OP-RU+ cells. CD3+ TRAV1-2+ MR1-5-OP-RU tetramer+ MAIT cells were analyzed for CD4/CD8, 438 
CD161/CD218 and CD161/CD27 expression. (b) Percentage MR1-5-OP-RU tetramer+ MAIT cells of 439 
total TRAV1-2+ population in thymus, cord blood, young and adult blood. (c) Stage 1 (CD161-CD218-) 440 
MAIT cells expressed as a percentage of total TRAV1-2+ MR1-5-OP-RU tetramer+ MAIT cells in 441 
thymus, cord blood, young and adult blood. (d) Percentages of CD4+CD8+ (DP), CD4+CD8-, and CD4-442 
CD8+ TRAV1-2+ MR1-5-OP-RU tetramer+ MAIT cells in human thymus and young blood. Donor 443 
matched samples are indicated with a line. (e) Percentage MR1-5-OP-RU tetramer+ MAIT cells of total 444 
TRAV1-2+ population in donor matched thymus and young blood samples. (f) Percentage MR1-5-OP-445 
RU tetramer+ MAIT cells of total CD3+ population in young blood samples. (g) Percentages of stage 1, 446 
stage 2, and stage 3 MR1-5-OP-RU tetramer+ MAIT cells in thymus, cord blood, young blood and adult 447 
blood. *P<0.1 **P<0.01 ***P<0.001 (Mann-Whitney rank sum U test (d)). Data show 9 samples for 448 
cord, young and adult blood and 12 thymus samples (a, b, c) or 5 thymus, 4 cord blood, 4 young blood 449 
and 5 adult blood (g). Stage 1 (S1, CD161-CD27-), stage 2 (S2, CD161-CD27+), and stage 3 (S3 450 
CD161+CD27+/lo) (a, g). 451 
 452 
Figure 8. Comparison of human MAIT cells from thymus and blood 453 
(a) Flow cytometric analysis of thymic stage 1 (S1, CD161-CD27-, blue), stage 2 (S2, CD161-CD27+, 454 
green) and stage 3 cells (S3, CD161+CD27+/lo, red) TRAV1-2+ MR1-5-OP-RU tetramer+ MAIT cells, 455 
young blood TRAV1-2+ MR1-5-OP-RU tetramer+ MAIT cells, and adult blood TRAV1-2+ MR1-5-OP-456 
RU tetramer+ MAIT cells for CD4/CD8, and CD8/CD8ȕ expression. (b) Flow cytometric analysis of 457 
double positive (DP) thymocytes, stage 1, stage 2, stage 3 thymic MAIT cells from thymus, and MAIT 458 
cells from matched donor young blood for PLZF, RORȖt and T-bet expression. (c) Flow cytometric 459 
analysis of stage 1, stage 2, and stage 3 MAIT cells following PMA/ionomycin stimulation (Stim) from 460 
enriched thymus and young blood, analyzed for IFN-Ȗ and TNF. (d) IFN-Ȗ and TNF producing stage 1, 461 
stage 2, and stage 3 MAIT cells expressed as a percentage of cytokine producing MAIT cells. ND = not 462 
detectable. Data are representative of 6 thymus samples and 6 young blood samples, and 5 adult blood 463 
samples (a), or of 5 thymus and 5 young blood samples (b), or of 4 thymus and 4 young blood donor 464 
samples (c, d; mean ± SEM). 465 
 466 
 467 
 468 
 469 
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Online Methods 470 
Mice 471 
C57BL/6 (B6) mice, MR1-deficient mice, TRAV1-TRAJ33 TCR transgenic C-/- mice, IL-18-deficient 472 
mice were all male, on a C57BL/6 background. Male CD1d-deficient mice on C57BL/6 and BALB/c 473 
backgrounds were bred in house at the Department of Microbiology and Immunology Animal House, 474 
University of Melbourne. PLZF-null male and female mice were generated and bred in house at the John 475 
Curtin School of Medical Research as previously described15. Germ-free male C57BL/6 and control SPF 476 
male C57BL/6 mice were generated at the Walter and Eliza Hall Institute Animal Facility. All 477 
procedures using mice were approved by the University of Melbourne Animal Ethics Committees, the 478 
Australian National University Animal Experimentation Ethics Committee, or by the Walter and Eliza 479 
Hall Institute Animal Ethics Committee. Droshafl/+ CD4-Cre heterozygous control mice and 480 
Droshafl/fl CD4-Cre mice, male and female, were generated and bred as previously described in30. Male 481 
IL-18Rα-deficient mice were generated and bred as previously described34. Single cell suspensions from 482 
mouse thymus, spleen, lung and inguinal lymph nodes were prepared as previously described15.  483 
 484 
Human blood and tissue  485 
Adult peripheral human blood samples were obtained from the Australian Red Cross Blood Service 486 
under agreement number 13-04VIC-07. Young human peripheral blood samples and matching thymus 487 
(donors ranged from 5 days to 14 years of age) were obtained from the Royal Children’s Hospital (RCH), 488 
Victoria, Australia. Umbilical cord blood samples were obtained from the Mercy Hospital for Women, 489 
Victoria, Australia. Experiments were conducted in accordance with University of Melbourne Human 490 
Research and Ethics committee guidelines (reference numbers 1035100 and 1443540), Mercy Health 491 
Human Research Ethics Committee Approval (reference number R14/25) and RCH Human Research 492 
Ethics Committee Approval (reference number 24131 G). Blood mononuclear cells were isolated by 493 
Ficoll-Paque PlusTM density gradient centrifugation (GE Healthcare). Donor thymi were cut into small 494 
pieces and passed through a 70 micron cell strainer into ice-cold RPMI-1640 medium containing 2mM 495 
EDTA before being washed into PBS + 2% Fetal Calf Serum (FACS buffer). 496 
 497 
Magnetic bead enrichment of thymic MAIT cells. 498 
Mouse and human MR1 tetramers were generated and biotinylated as previously described 2,19. 499 
Biotinylated MR1-5-OP-RU or control or Ac-6-FP monomers were tetramerized with streptavidin 500 
conjugated to either PE (SA-PE) (BD Pharmingen) or Brilliant Violet 421 (SA-BV) (Biolegend). Single 501 
cell suspensions of mouse thymus were prepared and stained with PE-mouse MR1-5-OP-RU tetramers 502 
prior to magnetic bead enrichment using anti-PE microbeads as per manufacturer’s instructions 503 
(Miltenyi Biotec). One independent enriched sample represents 3 pooled thymi unless otherwise 504 
specified. Single cell suspensions of human thymus were enriched for TRAV1.2+ cells by staining for 505 
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TRAV1.2-PE antibody, followed by magnetic bead enrichment using anti-PE microbeads (Miltenyi 506 
Biotec). 507 
 508 
Single cell TCR sequencing. 509 
MR1-5-OP-RU tetramer+ cells were single cell sorted based on CD24 and CD44 expression and cDNA 510 
prepared using SuperScript VILO (Invitrogen) as per manufacturer's instructions. Transcripts encoding 511 
different V and Vȕ genes were amplified using multiplex nested PCR as previously described43. PCR 512 
products were separated using a 1.5% agarose gel and sequenced by The Molecular Diagnostics Unit, 513 
University of Melbourne.  514 
 515 
Flow Cytometry. 516 
Mouse and human cells were stained with viability dye 7-aminoactinomycin D (7-AAD; Sigma) and the 517 
cell surface antibodies as listed in Supplementary Table 2. Cells were analyzed using a BD LSR Fortessa 518 
equipped with a 561nm yellow-green laser and data processed using FlowJo software (Treestar). Mouse 519 
cells are gated on B220- lymphocytes and human cells on CD14-CD19- lymphocytes after dead cell and 520 
doublet exclusion. Mouse MAIT cells were sorted using a BD FACSAriaIII cell sorter. 521 
 522 
Intracellular cytokine and intracellular transcription factor staining. 523 
Briefly, magnetic bead enriched MR1-5-OP-RU tetramer+ cells from mouse thymus and enriched 524 
TRAV1.2+ cells from human thymus were stimulated for 4h with PMA (10 ng/ml) and ionomycin (1 525 
μg/ml) in the presence of GolgiStop (BD Biosciences). Surface staining of the cells was then performed, 526 
before the cells were fixed and permeabilized using BD Cytofix/Cytoperm kit (BD Biosciences) as per 527 
manufacturer’s instructions. Cells were then stained for intracellular cytokines as listed in 528 
Supplementary Table 3. Transcription factors were assessed by staining with antibodies as listed in 529 
Supplementary Table 3 after the cells were surface-stained and permeabilized with the eBioscience 530 
Foxpγ Fixation/Permeabilization kit, according to the manufacturer’s instructions.  531 
 532 
OP9 co-culture differentiation assay. 533 
To verify the precursor-product relationship of mouse MAIT cells, an adaptation of the OP9 co-culture 534 
protocol similar to that previously described was used1. Briefly, OP9 cells were plated in flat 96-well 535 
plates at sub-confluency in complete tissue culture media (DMEM media supplemented with 10% (v/v) 536 
Fetal Calf Serum (FCS), 1x GlutaMAXTM (2mM L-Glutamine, Gibco) 15mM HEPES (Gibco), 0.1mM 537 
NEAA (non-essential amino acids, Invitrogen), 100U/ml penicillin (sodium salt, Gibco), 1mM sodium 538 
pyruvate (Invitrogen), 100μg/ml streptomycin sulfate (Gibco) and 50μM β-mercaptoethanol (Sigma). 539 
1x103 sort purified mouse thymus MAIT cells from stage 1 (CD24+CD44-), stage 2 (CD24-CD44-) or 540 
stage 3 (CD24-CD44+) were cultured in the presence or absence of OP9 stromal cells with media 541 
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supplemented with mouse IL-2 (50ng/ml, Peprotech). 10μg/ml of -MR1 blocking antibody (clone 542 
8F2.F9)2 was added in blocking experiments. Co-cultures were kept at 37oC at 5% CO2 for 5 days. MAIT 543 
cells were harvested, stained with antibodies and analyzed via flow cytometry.  544 
 545 
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